Although early investigations of heregulins in clinical breast cancer have failed to reveal an association between their expression and prognostic parameters [42,43], these studies tend to address expression of heregulin within the neoplastic epithelial cells rather than within the tumour stroma. This evidence concerns the gene NRG1 and breast carcinoma.